Oragenics, Inc. (OGEN) Monday said its lead drug candidate ONP-002, proposed for the treatment of concussion, has successfully completed an in vivo study to determine if multi-day treatments of ONP-002 cause DNA damage and increased risk of cancer. The shares were up more than 6 percent in pre-market to $1.49.
A concussion is a mild traumatic brain injury that affects brain function.
Results from the in vivo study showed that multi-day treatment for concussion using ONP-002 will not cause genotoxicity. The company said it plans to conduct a Phase 2 study of ONP-002 in concussed patients.
Oragenics stock had closed at $1.40, up 29.63 percent on Friday. It has traded in the range of $0.86 - $7.74 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.